A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-Year-Old Healthy Adolescents and Adults

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2021
The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults and the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to \<18-year-old EBV-seronegative healthy adolescents.
Epistemonikos ID: 486264b79b328d6338d9fab624e9286a52a8abc5
First added on: Oct 02, 2023